CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 8 enrolled
Drug / intervention
Deucravacitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06476834
NCT06476834Phase 4Completed

A Phase IV, Open-label, Single-group, Single-dose Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

Bristol-Myers Squibb·interventional·Posted Jun 26, 2024·Updated Dec 3, 2025

In Brief

A Phase 4 clinical trial evaluating Deucravacitinib for Healthy Volunteers. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate Deucravacitinib concentrations in the breast milk and plasma of healthy lactating female participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20252026
First PostedJun 26, 2024
Enrollment StartJun 24, 2024
Primary CompletionNov 2, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.0 years ago

Interventions

Deucravacitinibdrug

Specified dose on specified days